Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of prkar1a and pten in mice

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages

  Pringle, Daphne R ^a,e   Vasko, Vasily V ^c   Yu, Lianbo ^a   Manchanda, Parmeet K ^a   Lee, Audrey A ^a   Zhang, Xiaoli ^a   Kirschner, Jessica M ^a   Parlow, Albert F ^d   Saji, Motoyasu ^b   Jarjoura, David ^a   Ringel, Matthew D ^b   La Perle, Krista M D ^a   Kirschner, Lawrence S ^a,b  

^a Center for Biostatistics   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRKAR1A GENE; PROTEIN EXPRESSION; PTEN GENE; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84899954445     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3101     Document Type: Article

References (40)

1. Sugino K, Ito K, Nagahama M, et al. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid. 2011;21:751-757.
2. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400-407.
3. Bertherat J Horvath A Groussin L et al. Mutations in regulatory subunit type 1A of cyclic a denosine 5-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes J Clin Endocrinol Metab. 2009 94 2085-2091
4. NgeowJ, Mester J, Rybicki LA, Ni Y, MilasM,Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals withCowdenand Cowden-like syndrome characterized by germline PTEN, SDH, or K LLN alterations. J Clin Endocrinol Metab. 2011;96:E2063-2071.
5. Sandrini F, Matyakhina L, Sarlis NJ, et al. Regulatory subunit type I-of protein kinase A (PRKAR1A): a tumor-suppressor gene for spo radic thyroid cancer. Genes Chromosomes Cancer. 2002;35: 182-192.
6. Kirschner LS, Kusewitt DF, Matyakhina L, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cycl ic AMP-responsive tissues. Cancer Res. 2005;65:4506-4514.
7. Kirschner LS. Use of mouse models to understand the molecular basis of tissue-specific tumorigenesis in the Carney complex. J Intern Med. 2009;266:60-68.
8. Pringle DR, Yin Z, Lee AA, et al. Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer. Endocr Relat Cancer. 2012;19:435-446.
9. Jones GN, Manchanda PK, Pringle DR, Zhang M, Kirschner LS. Mouse models of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2010;24:451-460.
10. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res. 2007;6 7:959-966.
11. Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A. Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a high er incidence in females. Oncogene. 2010;29:5678-5686.
12. Yeager N, Brewer C, Cai KQ,XuXX, Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiat ed proliferative signals in the thyroid follicular epithelium. Cancer Res. 2008;68:444-449.
13. Vasko V, Saji M, Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet. 2004;41:161-170.
14. Testa JR, Bellacosa A. Membrane translocation and activation of the Akt kinase in growth factor-stimulated hematopoietic cells. Leuk Res. 1997;21:1027-1031.
15. Mulholland DJ, TranLM,Li Y, et al. Cell autonomous role ofPTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19:792-804.
16. Du K, Tsichlis PN. Regulation of the Akt kinase by interacting proteins. Oncogene. 2005;24:7401-7409.
17. Nadella KS, Kirschner LS. Disruption of protein kinase a regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res. 2005;65:10307-10315.
18. Weber F, Shen L, Aldred MA, et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab. 2005;90:2512-2521.
19. Tsygankova OM, Saavedra A, Rebhun JF, Quilliam LA, Meinkoth JL. Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol Cell Biol. 2001;21:1921-1929.
20. Lou L, Urbani J, Ribeiro-Neto F, Altschuler DL. cAMP inhibition of Akt is mediated by activated and phosphorylated Rap1b. J Biol Chem. 2002;277:32799-32806.
21. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999;68:821-861.
22. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809-814.
23. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA. 2011;108:1615-1620.
24. Mavrakis M Lippincott-Schwartz J Stratakis CA Bossis I. mTOR kinase and the regulatory subunit of protein kinase A (PRKAR1A) spatially and functionally interact during autophagosome maturation Autophagy. 2007 3: 151-153.
25. Day ME, Gaietta GM, Sastri M, et al. Isoform-specific targeting of PKA to multivesicular bodies. J Cell Biol. 2011;193:347-363.
26. Blancquaert S, Wang L , Paternot S, et al. cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol. 2010;24:1453-1468.
27. Chaturve di D, Cohen MS, Taunton J, Patel TB. The PKARI-subunit of protein kinase A modulates the activation of p90RSK1 and its function. J Biol Chem. 2009;284:23670-23681.
28. Brewer C, Yeager N, Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 2007;67:8002-8006.
29. Aroor AR, Jackson DE, Shu kla SD. Dysregulated phosphorylation and nuclear translocation of cyclic AMP response element binding protein (CREB) in rat liver after chronic ethanol binge. Eur J Pharmacol. 2012;679:101-108.
30. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278:16-27.
31. Saji M, Narahara K, McCarty SK, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene. 2011;30:4307-4315.
32. McCarty SK, Saji M, Zhang X, et al. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer. 2010; 17:989-999.
33. Xie J, Ponuwei GA, Moore CE, Willars GB, Tee AR, Herbert TP. cAMP inhibits mammalian target of rapamycin complex-1 and-2 (mTORC1and 2) by promoting complex dissociation and inhibiting mTOR kinase a ctivity. Cell Signal. 2011;23:1927-1935.
34. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S. Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis. 2004;39:212-216.
35. Trimboli AJ, Cantemir-Stone CZ, Li F, et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature. 2009;461: 1084-1091.
36. Jones GN, Tep C, TownsWH2nd, et al. Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia. 2008;10:1213-1221.
37. Saeed A I, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374-378.
38. Huang da W, Sherman BT, Zheng X, et al. Extracting biological meaning from large gene lists with DAVID. Curr Protoc Bioinformatics. 2009;Chapter 13:Unit 13.11.
39. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
40. Yu L, Gulati P, Fernandez S, Pennell M, Kirschner L, Jarjoura D. Fully moderated T-statistic for sm all sample size gene expression arrays. Stat Appl Genet Mol Biol. 2011;10.